ArticleEndocrine pathology2025
Intratumoral Heterogeneity of Ki67 Index and Its Impact on the Diagnosis and Prognostication of Pancreatic Neuroendocrine Tumors: Hot-Spot Count Differs Significantly from Random-Area Count.
Article in Endocrine pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Comment on "Role of extracellular volume fraction determined by dual-layer spectral detector CT in predicting the tumor grade of pancreatic neuroendocrine neoplasms".Japanese journal of radiology · 2026Article
- Article
- Comprehensive Immunophenotypic Profiling and Prognostic Value in Salivary Gland Mucoepidermoid Carcinoma.International dental journal · 2026Article
- Refining Prognostic Stratification in Grade 2 Pancreatic Neuroendocrine Tumors.Annals of surgical oncology · 2026Article
- Revisiting Ki-67 Assessment in Canine Mast Cell Tumours: From Manual Hotspot to Automated Global Analysis.Veterinary sciences · 2026Article
- Clinical application of digital pathology in small intestinal neuroendocrine tumours: proposal of a new G0 category.Endocrine oncology (Bristol, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pivotal role of Ki67 in grading pancreatic neuroendocrine tumors (PanNETs) is well recognized and firmly established in current WHO guidelines. Intratumoral heterogeneity is a well-known phenomenon, and it has also been documented for Ki67; however, the data on the magnitude of the impact of this heterogeneity on the final grade in primary NETs is relatively limited. In this study, Ki67 labeling index (KI) was calculated by using the manual count of camera-captured image method in 91 PanNETs both in hot-spots (KI(h)) as well as 6 different random-areas (KI(r)), each counted in a minimum of 2000 cells. The process was repeated for 29 samples from metastatic foci. Mean KI of the hot-spots was more than twofold higher than that of the random (5 vs 2.1%), with a low kappa agreement (0.2770). This changed the final grade in almost half of the cases (42/91; p < 0.001). Random counting missed all 4 G3 NETs as well as 6/7 of the Grade 2b cases (those with Ki67 10-≤ 20%). On the other hand, in only 4 cases, the difference in KI was > 10%. Similar heterogeneity was also observed in the 29 metastatic tumors analyzed with the final grade differing in 55% based on KI(h) versus KI(r). KI(h) had a stronger correlation with signs of aggressiveness including metastasis and tumor size and also trended with perineural invasion in tumors > 5 cm. The intratumoral heterogeneity in Ki67 in pancreatic NETs lead to a change in final grade in 46% of cases by hot-spot versus random count. This underscores the importance of both making a reliable Ki67 count and providing a numerical index in addition to the final grade, and interpretation of the results case-by-case basis for management purposes, rather than the rigid grade-based approach. This study also supports the usage of hot-spot rather than random count as the grade parameter. Reporting Ki67 in cytology and small biopsy specimens should be supplemented by a comment highlighting that the final grade may change when the entire tumor is evaluated but that the difference in the nominal count will seldom be higher than 10%.
Indexed as
Identifiers
41076497What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.